Liver cancer is the 4th leading cause of cancer-related deaths worldwide, being the 2nd and 6th most common cause of cancer death in men and women, respectively, but represents the 1st cause of death in cirrhotic patients.
Most of liver cancers are hepatocellular carcinomas, however some patients develop intrahepatic cholangiocarcinomas (ICC) or rare tumours in non-cirrhotic livers. Chronic liver diseases, alcohol consumption, obesity and diabetes, non-alcoholic fatty liver disease (NAFLD), aflatoxins exposure as well as chronic infection with HBV or HCV are considered as risk factors.
Recently, the 2020 Nobel Prize has awarded 3 scientists for their discovery and their valuable contribution to the elimination of HCV which lead to cirrhosis and liver cancer.
The burden of adult liver cancers and HCC is still increasing and various public health strategies have been developed for the prevention and control of this trend which will likely remain a major public health problem worldwide in the upcoming decades , .
EASL is offering the liver community a collection of open-access educational resources on liver cancer, developed with worldwide experts in the field. These diverse resources range from the online HCC management course, to Clinical Practice Guidelines, Best of ILC Slide Decks, educational materials from EASL events, and a collection of articles from the Journal of Hepatology.
EASL is building strong relationships with patient associations and public health organisations, so that together we can improve patients’ lives and reduce stigma.
Most common etiologies related to liver cancer
Chronic Viral Hepatitis
(B or C)
New liver cancer resources
In this audio interview conducted on the occasion of liver cancer awareness month, Dr. Massimo A. Iavarone, hepatologist at the Ospedale Maggiore in Milan, Italy, is answering key questions raised by the Liver Patients International (LPI) and PSC Support, two EASL-affiliated patient associations, both part of the EASL patient synergies project.
Dr. Massimo A. Iavarone is an assistant in the Department of Internal Medicine, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca’ Granda Maggiore, Hospital of Milan, Italy. His main expertise and research interest is about the systemic treatments of hepatocellular carcinoma. He is a steering committee member and a member of the Drugs Commission of the Italian Association for the Study of the Liver (IASL) Special Interest Group on hepatocellular carcinoma.
Click on the image to play the podcast.
Digital ILC 2020 Takeaways - Liver tumours
In this EASL Takeaway, Prof. Maria Reig, Prof. Markus Peck, and Prof. Helen Reeves review the latest advances in cancer therapy, diagnostics, and prognostics presented at Digital ILC 2020.
Digital ILC 2020
All content is available exclusively to registered delegates. Browse through the resources, including Best of Digital Liver Tumours Slide Decks, abstract & interactive sessions, ePosters, and more.
Nurses & AHPs at Digital ILC 2020
At Digital ILC 2020, nurses and AHPs held dedicated sessions on Liver Tumours, highlighting their engagement and the importance of their role in improving patients’ lives.
Liver Cancer Summit 2020
Learn from the latest science on liver cancer, presented at the most important European summit on this topic.
HCC Summit 2019
Discover 150+ open-access materials (including presentations, posters, etc.) from the HCC Summit 2019.
EASL Clinical Practice Guidelines
These CPGs give up-to-date advice on the clinical management of HCC patients and the management of benign liver tumours. Each CPG has a downloadable Slide Deck.
European Network for the Study of Cholangiocarcinoma (ENS-CCA)
The European Network for the Study of Cholangiocarcinoma (ENS-CCA) is an open, international network of scientists focused on the multidisciplinary study of CCA. This pan-European consortium was created in 2015 with the main aim of promoting collaborative research projects at the basic, translational and clinical levels.
The ENS-CCA is coordinating a European Registry of patients with CCA (competitively funded by EASL in 2016 and in 2019) with clinical, biochemical, histological information using the online platform REDCap. This registry is the basis of multiple ongoing collaborative projects, which include the use of biological samples of patients from participating institutions.
Save the date
 European Association for the Study of the Liver. Electronic address: firstname.lastname@example.org; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. Erratum in: J Hepatol. 2019 Apr;70(4):817. PMID: 29628281.
 Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014 Jun;60(6):1268-89. doi: 10.1016/j.jhep.2014.01.021. Epub 2014 Mar 27. PMID: 24681130.